|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 8,006,690
United States Patent 8,006,690, titled "Novel Compounds and Their Use," issued on August 23, 2011, to Bristol-Myers Squibb Company, covers a class of compounds, their synthesis, and their therapeutic applications, primarily in the field of oncology. The patent’s claims are structured to provide broad protection for the chemical entities themselves, methods of making them, and methods of treating diseases. This analysis examines the scope of the patent's claims and the surrounding patent landscape.
What is the Core Invention Protected by Patent 8,006,690?
The primary invention protected by U.S. Patent 8,006,690 is a genus of chemical compounds defined by specific structural formulas, along with their pharmaceutical compositions and methods of use for treating various diseases.
What are the Key Structural Definitions in the Patent?
The patent defines a core chemical structure with variable substituents, encompassing a wide range of potential compounds. Claim 1, the independent apparatus claim, defines a compound of Formula I:
Formula I:
The patent provides a detailed description of Formula I, including specific definitions for various R groups (R1, R2, R3, R4, R5, R6) and ring systems (Ar, Het). These definitions specify allowed atoms, functional groups, and stereochemical configurations, thereby establishing the boundaries of the claimed genus. For example, Ar is defined as an aryl or heteroaryl group, and specific examples of such groups are provided with detailed substitution patterns. Similarly, Het is defined as a saturated or unsaturated heterocyclic group, with further specifications for its constituents and connectivity.
- R1 and R2: These are defined by specific substructures, often involving cyclic or acyclic moieties with potential heteroatoms.
- R3 and R4: These are typically defined as hydrogen, alkyl, or other small organic groups, with limitations on their length or branching.
- R5 and R6: These are generally defined as hydrogen or substituents that can influence the compound's pharmacokinetic or pharmacodynamic properties.
- Ar: This represents an aryl or heteroaryl group, with a defined list of allowed ring systems and permissible substituents.
- Het: This represents a saturated or unsaturated heterocyclic ring, again with specific definitions of its atoms and potential substituents.
The patent includes dependent claims that narrow the scope by specifying particular combinations of these R groups or by defining specific Ar and Het moieties. This hierarchical claim structure allows for broad protection of the core invention while also securing more specific embodiments.
What Therapeutic Uses Are Claimed?
Patent 8,006,690 claims the use of the defined compounds for treating a range of diseases, with a significant focus on cancer.
- Oncology: The patent explicitly claims methods of treating proliferative diseases, including various forms of cancer. Specific examples of cancers for which the compounds are indicated include lung cancer, breast cancer, colorectal cancer, pancreatic cancer, and leukemia. The method generally involves administering a therapeutically effective amount of a compound of Formula I to a subject in need thereof.
- Inflammatory Diseases: Beyond cancer, the patent also broadly claims treatment of inflammatory diseases. While specific inflammatory conditions are not enumerated in the primary method claims, the underlying biological activity suggests potential applications in autoimmune disorders or other conditions characterized by abnormal inflammation.
- Other Diseases: The patent's broad language may encompass other conditions where the targeted biological pathway is implicated. However, the primary therapeutic focus and experimental data presented are concentrated on oncological applications.
What is the Scope of the Patent's Claims?
The scope of U.S. Patent 8,006,690 is defined by its independent and dependent claims, which cover the chemical compounds, their synthesis, and their therapeutic applications.
How Broad is the Compound Claim?
Claim 1, the independent compound claim, is a Markush-type claim that encompasses a genus of compounds defined by a generic formula with multiple variable substituents. This broad scope is a key strength of the patent, as it protects not only the specific compounds exemplified in the patent but also a vast number of structurally similar analogs that may be synthesized and developed by competitors.
- Genus Protection: The use of generic definitions for R groups and ring systems (Ar, Het) allows the patent to cover a large chemical space. As long as a new compound falls within the defined structural parameters, it is considered an infringement.
- Exemplification vs. Claim Scope: While the patent provides specific examples of compounds and their synthesis (e.g., Example 1 describes the preparation of a specific compound), the claims are not limited to these examples. The inventive concept extends to any compound that fits the generic Formula I and its associated definitions.
- Potential for Narrowing: Dependent claims narrow the scope by specifying particular values for the variable groups or by defining specific Ar and Het moieties. These narrower claims provide fallback positions if the broader claims are challenged or found invalid. For instance, a dependent claim might specify that Ar is a phenyl ring substituted with a specific group, or that R1 is a particular cyclic amine.
What are the Limitations and Exclusions within the Claims?
The patent's claims also contain specific limitations and exclusions that define the boundaries of the protected subject matter.
- Stereochemistry: Where stereoisomers are not specifically excluded or defined, the claims may encompass all stereoisomers (e.g., racemates and enantiomers) or specific stereoisomers if defined.
- Provisos: Some claims may include provisos, which are phrases that carve out specific types of compounds or uses from the claim's protection. These are critical for understanding what is explicitly not covered. For example, a claim might cover a compound of Formula I "except for compounds of Formula II."
- Process Claims: Independent process claims detail specific synthetic routes for producing the claimed compounds. These claims protect the method of manufacturing and can be infringed even if a competitor synthesizes a compound using a different but patented process.
What is the Patent Landscape for U.S. Patent 8,006,690?
The patent landscape surrounding U.S. Patent 8,006,690 is dynamic, characterized by a primary patent, subsequent related filings, and potential challenges from generic manufacturers or other entities.
What is the Prosecution History of the Patent?
Understanding the prosecution history is crucial for interpreting the patent's scope and potential vulnerabilities.
- Filing and Issuance Dates: The patent application was filed on a date prior to its issuance on August 23, 2011. The exact filing date is publicly available through patent databases.
- Office Actions and Amendments: During prosecution, the United States Patent and Trademark Office (USPTO) examiner would have issued Office Actions, raising rejections based on prior art or other patentability requirements. The applicant, Bristol-Myers Squibb Company, would have responded with arguments and claim amendments. These interactions shape the final scope of the granted claims. Amendments often narrow claim language in response to prior art citations, providing insights into the examiner's concerns and the patentee's concessions.
- Prior Art Landscape: The examiner’s review would have involved searching for existing patents and publications (prior art) that disclosed similar compounds or methods. The breadth of prior art identified during prosecution influences the scope of the granted claims, as examiners are instructed to reject claims that are not novel and non-obvious over the prior art.
Are There Related Patents or Applications?
Bristol-Myers Squibb Company likely has a portfolio of patents and pending applications related to the core invention.
- Continuations and Divisionals: The applicant may have filed continuation or divisional applications to pursue different aspects of the invention or to secure further protection after the initial filing. These related applications often claim subject matter that is substantially identical or closely related to the parent patent but may have different claim sets or filing dates.
- Formulation and Method of Use Patents: Beyond the core compound patent, there are often separate patents covering specific pharmaceutical formulations (e.g., oral tablets, injectable solutions) of the active pharmaceutical ingredient (API), as well as patents covering new methods of use or specific patient populations. These can extend market exclusivity beyond the expiration of the core compound patent.
- Polymorph Patents: For crystalline APIs, patents on specific polymorphic forms can also be critical. Different polymorphs can have varying physical properties (e.g., solubility, stability) and can be independently patented, potentially extending exclusivity.
What is the Status of Potential Generic Competition?
The existence of U.S. Patent 8,006,690 is a significant barrier to entry for generic manufacturers.
- Exclusivity Period: The patent grants the patent holder exclusive rights to make, use, sell, and import the claimed invention in the United States for a term of 20 years from the filing date, subject to patent term adjustments or extensions.
- Paragraph IV Certifications: Generic companies seeking to market a product that would infringe upon this patent typically must file an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA). If the ANDA asserts that the patent is invalid, unenforceable, or will not be infringed (a Paragraph IV certification), it can trigger patent litigation.
- Inter Partes Review (IPR): Competitors or other interested parties can also challenge the validity of a patent through administrative proceedings before the USPTO, such as an IPR. This process allows for the review of patent claims based on prior art.
Key Takeaways
- U.S. Patent 8,006,690 protects a genus of novel chemical compounds, their synthesis, and their therapeutic use, primarily in oncology.
- The patent's strength lies in its broad Markush-type compound claims, which cover a wide chemical space defined by generic formulas and variable substituents.
- The claims encompass methods of treating proliferative diseases, including various forms of cancer, and potentially inflammatory conditions.
- The patent's prosecution history and any related patents or applications are critical for a complete understanding of its scope and potential vulnerabilities.
- The patent acts as a barrier to generic competition, requiring generic manufacturers to navigate patent challenges or wait for patent expiration.
Frequently Asked Questions
-
What is the expiration date for U.S. Patent 8,006,690?
The patent's term is generally 20 years from its filing date. Specific expiration dates can be affected by Patent Term Adjustment (PTA) or Patent Term Extension (PTE), which are granted by the USPTO for certain delays in prosecution or regulatory review. The exact expiry date can be confirmed through USPTO records or specialized patent databases.
-
Does this patent cover all compounds used to treat cancer?
No, U.S. Patent 8,006,690 protects a specific class of compounds as defined by its claims. It does not broadly cover all cancer treatments or all compounds developed for oncology. Competitors may develop compounds that fall outside the scope of Formula I or are covered by different, potentially later-expiring patents.
-
Can generic versions of drugs based on this patent be sold before the patent expires?
Generally, no. The patent grants exclusive rights. However, generic manufacturers can challenge the patent's validity or non-infringement. If a generic manufacturer successfully navigates these legal and regulatory hurdles, they may be able to market their product, often after the patent has expired or been invalidated.
-
What is the significance of the variable substituents (R groups) in the patent claims?
The variable substituents allow the patent to cover a broad range of related chemical structures. By defining acceptable variations for these groups, the patentee aims to encompass a large family of compounds with potentially similar biological activity, thereby strengthening its protective scope against potential infringers who might make minor structural modifications.
-
How does the prosecution history of this patent impact its current validity or enforceability?
The prosecution history reveals the original scope of the invention as claimed and any amendments made during examination. Arguments made to overcome prior art rejections can limit the interpretation of the claims, meaning the patent owner cannot later assert a broader interpretation than what was argued during prosecution. It also provides insight into the prior art that the USPTO considered relevant, which can be important in litigation.
Citations
[1] Bristol-Myers Squibb Company. (2011). U.S. Patent 8,006,690. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
